首页> 美国卫生研究院文献>Frontiers in Neurology >Increased Circulating Exosomal miRNA-223 Is Associated with Acute Ischemic Stroke
【2h】

Increased Circulating Exosomal miRNA-223 Is Associated with Acute Ischemic Stroke

机译:增加的循环外泌体miRNA-223与急性缺血性中风有关。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recent studies have demonstrated that exosomal microRNAs (miRNAs) are novel biomarkers and therapeutic targets for various diseases including vascular disease. However, specific exosomal miRNAs expression in stroke patients has not been reported yet. Here, we explored whether circulating exosomal miRNAs can serve as potential biomarkers for the diagnosis of acute ischemic stroke and discussed the potential for clinical application. Blood samples were collected from acute ischemic stroke patients within the first 72 h (n = 50). Circulating exosomes were exacted by Exoquick exosome isolation kit and characterized by transmission electron microscopy. Western blot was performed to assess the expression of exosomal protein makers. Exosomal miRNA-223 (miR-223) was detected by RT-PCR assay. The relationship between the expression levels of miR-223 and National Institutes of Health Stroke Scale (NIHSS) scores, brain infarct volume, and neurological outcomes were analyzed. Circulating exosomes were isolated and the size of vesicles ranged between 30 and 100 nm. The identification of exosomes was further confirmed by the detection of specific exosomal protein markers CD9, CD63, and Tsg101. Exosomal miR-223 in acute ischemic stroke patients was significantly upregulated compared to control group (p < 0.001). Exosomal miR-223 level was positively correlated with NIHSS scores (r = 0.31, p = 0.03). Exosomal miR-223 expression in stroke patients with poor outcomes was higher than those with good outcomes (p < 0.05). Increased exosomal miR-223 was associated with acute ischemic stroke occurrence, stroke severity, and short-term outcomes. Future studies with large sample are needed to assess the clinical application of exosomal miR-223 as a novel biomarker for ischemic stroke diagnosis.
机译:最近的研究表明,外泌体微小RNA(miRNA)是新型的生物标志物,是包括血管疾病在内的各种疾病的治疗靶标。然而,尚未报道中风患者中特定的外泌体miRNA表达。在这里,我们探讨了循环的外泌体miRNA是否可以作为诊断急性缺血性中风的潜在生物标志物,并讨论了其临床应用潜力。在最初的72小时内(n = 50)从急性缺血性中风患者中采集血液样本。用Exoquick外泌体分离试剂盒精确测定循环外泌体,并用透射电子显微镜进行表征。进行蛋白质印迹以评估外泌体蛋白制造者的表达。通过RT-PCR检测外泌体miRNA-223(miR-223)。分析了miR-223的表达水平与国立卫生研究院卒中量表(NIHSS)评分,脑梗死体积和神经系统结局之间的关系。分离出循环外泌体,囊泡大小在30至100nm之间。通过检测特定的外泌体蛋白标记CD9,CD63和Tsg101,进一步证实了外泌体的鉴定。与对照组相比,急性缺血性中风患者的外泌体miR-223显着上调(p <0.001)。外泌体miR-223水平与NIHSS得分呈正相关(r = 0.31,p = 0.03)。结果差的卒中患者的外体miR-223表达高于结果好的患者(p <0.05)。外泌体miR-223的增加与急性缺血性中风的发生,中风的严重程度和短期预后相关。需要大量样品的未来研究来评估外泌体miR-223作为缺血性中风诊断的新型生物标志物的临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号